Patents by Inventor Xuesai Zhang

Xuesai Zhang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Antibody Binding to Human IL-33, Preparation Method Therefor, and Use Thereof
    Publication number: 20230399394
    Abstract: The present invention relates to an antibody binding to human IL-33 or an antigen-binding fragment thereof, which can bind to the human IL-33 with a high affinity and block the binding of ST2 to IL-33, can be used in the preparation of a drug for treating diseases with a high IL-33 expression (such as asthma, atopic/allergic dermatitis, chronic rhino sinusitis and chronic obstructive pulmonary diseases (COPD)), and has good clinical application prospects.
    Type: Application
    Filed: September 26, 2021
    Publication date: December 14, 2023
    Applicant: SUNSHINE GUOJIAN PHARMACEUTICAL (SHANGHAI) CO., LTD.
    Inventors: Wei Guo, Xuesai Zhang, Huiting Xu, Qingrou Li, Le Zhao, Jianhe Chen, Haomin Huang, Zhenping Zhu
  • TISSUE FACTOR-TARGETED ANTIBODY-DRUG CONJUGATE
    Publication number: 20230138930
    Abstract: A tissue factor (TF)-targeted antibody-drug conjugate (ADC) and a method for preparing the ADC. The ADC is capable of binding to TF antigen with high specificity, and has high affinity, low immunogenicity, high cytotoxicity, and significant anti-tumor activity.
    Type: Application
    Filed: October 27, 2022
    Publication date: May 4, 2023
    Inventors: Ke YU, Jingkang SHEN, Tao MENG, Lanping MA, Xuesai ZHANG, Qingrou LI, Qing LIN
  • Tissue factor-targeted antibody-drug conjugate
    Patent number: 11534495
    Abstract: A tissue factor (TF)-targeted antibody-drug conjugate (ADC) and a method for preparing the ADC. The ADC is capable of binding to TF antigen with high specificity, and has high affinity, low immunogenicity, high cytotoxicity, and significant anti-tumor activity.
    Type: Grant
    Filed: June 9, 2017
    Date of Patent: December 27, 2022
    Assignees: FUDAN UNIVERSITY, SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES, SHANGHAI MIRACOGEN INC.
    Inventors: Ke Yu, Jingkang Shen, Tao Meng, Lanping Ma, Xuesai Zhang, Qingrou Li, Qing Lin
  • ANTIBODY BINDING TO HUMAN HER2 AND PREPARATION METHOD AND USE THEREOF
    Publication number: 20210309759
    Abstract: Provided is an antibody binding to human HER2 or an antigen-binding fragment thereof capable of specifically binding to human HER2. Compared with Perjeta, the combination of the antibody or an antigen-binding fragment thereof and Herceptin has improved biological activity in inhibiting the proliferation of tumor cells overexpressing HER2. The antibody or an antigen-binding fragment thereof has an antigen-binding epitope different from known antibodies binding to human HER2, can be used to prepare a drug for treating a disease related to HER2 overexpression, such as cancer, and has good prospects for clinical application.
    Type: Application
    Filed: August 1, 2019
    Publication date: October 7, 2021
    Inventors: Jianhe CHEN, Xuesai ZHANG, Le ZHAO, Fei XU, Qingrou LI, Haomin HUANG, Zhenping ZHU
  • Antibody targeted to tissue factor, preparation method therefor, and use thereof
    Patent number: 10676537
    Abstract: The present invention provides a tissue factor (TF) monoclonal antibody and a preparation method therefor. The monoclonal antibody provided by the present invention can specifically bind with a TF antigen, has high affinity and low immunogenicity, and has the activity of resisting tumors and the like.
    Type: Grant
    Filed: February 20, 2017
    Date of Patent: June 9, 2020
    Assignees: Fudan University, Shanghai Miracogen Inc.
    Inventors: Ke Yu, Xuesai Zhang, Qing Lin, Qingrou Li
  • TISSUE FACTOR-TARGETED ANTIBODY-DRUG CONJUGATE
    Publication number: 20190201543
    Abstract: A tissue factor (TF)-targeted antibody-drug conjugate (ADC) and a method for preparing the ADC. The ADC is capable of binding to TF antigen with high specificity, and has high affinity, low immunogenicity, high cytotoxicity, and significant anti-tumor activity.
    Type: Application
    Filed: June 9, 2017
    Publication date: July 4, 2019
    Inventors: Ke Yu, Jingkang Shen, Tao Meng, Lanping Ma, Xuesai Zhang, Qingrou Li
  • ANTIBODY TARGETED TO TISSUE FACTOR, PREPARATION METHOD THEREFOR, AND USE THEREOF
    Publication number: 20190177431
    Abstract: The present invention provides a tissue factor (TF) monoclonal antibody and a preparation method therefor. The monoclonal antibody provided by the present invention can specifically bind with a TF antigen, has high affinity and low immunogenicity, and has the activity of resisting tumors and the like.
    Type: Application
    Filed: February 20, 2017
    Publication date: June 13, 2019
    Inventors: Ke Yu, Xuesai Zhang, Qing Lin